> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Creates CBER Safety Council
- URL: https://www.fdaweb.com/fda-creates-cber-safety-council/
- Published: 2026-11-19T19:58:29.000Z
- Updated: 2026-11-19T19:58:29.000Z
- Author: David McFarland
- Tags: Biologics

FDA says it has established a new CBER Safety Council, evolving from its longstanding Safety Working Group, to strengthen post-market safety oversight for products regulated by the Center. The new council will be separate from the CBER product offices, an agency [statement](https://www.fda.gov/vaccines-blood-biologics/whats-new-biologics/fda-establishes-cber-safety-council-strengthen-postmarketing-oversight-biological-products?ref=fdaweb.com) says, reporting directly to the CBER director.

“By bringing together senior scientific and regulatory experts from across the center,” the statement says, “the new council provides a layer of review that is distinct from the product offices that conduct premarket approval, ensuring that safety assessments that support post-marketing actions are comprehensive and consistent, and the scientific evidence behind FDA’s decisions is transparently communicated to the public.”

FDA says the council will:

- review and assess post-market safety signals across all CBER-regulated product categories;
- conduct structured benefit-risk assessments for regulatory action recommendations;
- recommend regulatory actions to CBER leadership in connection with Title IX of the FDA Amendments Act for safety reviews under Section 921 Safety Labeling Changes, Risk Evaluation and Mitigation Strategies, and Safety-related Postmarketing Requirements;
- recommend regulatory actions to CBER leadership for safety-related market withdrawals;
- recommend regulatory actions to CBER leadership on post-approval studies mandated in a PMA order or regulation for Class 3 devices and any postmarketing surveillance studies required by order at the time of approval or clearance or any time thereafter of certain Class 2 devices;
- publish public-facing safety communications promptly after significant safety determinations, ensuring the public is informed promptly and with clear documentation of the evidence underlying each decision; and
- coordinate with external partners, including CDC, NIH, and international regulatory authorities.